A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets

Frontiers in Oncology

Si Zhou¹  Hai-Xi Sun¹  Songming Liu¹  Lijian Zhao² 

[1] College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China;College of Medical Technology, Hebei Medical University, Shijiazhuang, China;

关键词: breast cancer;    neoantigens;    immunotherapy;    PIK3CA;    SNVs;   

DOI  :  10.3389/fonc.2022.786438

来源: DOAJ

【 摘 要 】

Neoantigens are mutated antigens specifically generated by cancer cells but absent in normal cells. With high specificity and immunogenicity, neoantigens are considered as an ideal target for immunotherapy. This study was aimed to investigate the signature of neoantigens in breast cancer. Somatic mutations, including SNVs and indels, were obtained from cBioPortal of 5991 breast cancer patients. 738 non-silent somatic variants present in at least 3 patients for neoantigen prediction were selected. PIK3CA (38%), the highly mutated gene in breast cancer, could produce the highest number of neoantigens per gene. Some pan-cancer hotspot mutations, such as PIK3CA E545K (6.93%), could be recognized by at least one HLA molecule. Since there are more SNVs than indels in breast cancer, SNVs are the major source of neoantigens. Patients with hormone receptor-positive or HER2 negative are more competent to produce neoantigens. Age, but not the clinical stage, is a significant contributory factor of neoantigen production. We believe a detailed description of breast cancer neoantigen signatures could contribute to neoantigen-based immunotherapy development.

【 授权许可】

Unknown